SPECIALITY MEDICINES
SPMLVerifiedSPECIALITY MEDICINES is a publicly traded security listed on the BSE exchange.
Stock Snapshot & Key Numbers — SPECIALITY MEDICINES
Verified Daily CloseOfficial closing price, 1-year price range, valuation multiples, and market value from exchange records.
SPECIALITY MEDICINES (SPML) is a Indian equity security listed on the BSE with ISIN BSE:544738. As of the last recorded market session on Close on 16 Oct 2026, the stock closed at ₹169.95, recording a +0.00 (+0.00%) advance from its previous close of ₹169.95. Over the trailing 52-week trading cycle, SPML has traded between a 52-week low of ₹125.90 and a 52-week high of ₹363.05, establishing its annual trading channel. In historical performance, SPECIALITY MEDICINES has gained 34.99% over the past 1 year. Period returns across standard measurement intervals include: 1-week: +0.86%, 1-month: +9.68%, 6-month: -17.26%, 1-year: +34.99%, 3-year: +34.99%, 5-year: +34.99%. Daily reported trading volume reached standard market liquidity units. On key valuation multiples as of 11 Oct 2026, the company trades at a trailing price-to-earnings (P/E) multiple of 11.3x and a price-to-book (P/B) ratio of 2.1x, with a trailing dividend yield of 0.00%. Its market capitalization stands at ₹148.04 Cr. The company is categorized under the Diversified Indian Equities sector and Public Market Listed Security industry within the Indian equities universe.
Price Chart
Trading Multiples & Ranges
Price boundaries and liquidity distribution.
How Outside Factors Affect This Stock (Market, Crude Oil & Currency)
How closely this stock moved with the broader market index, crude oil, and the exchange rate over the past year.
| Factor / Benchmark | 1Y Beta (Sensitivity) | 1Y Correlation (-1 to +1) | What This Means |
|---|---|---|---|
| NIFTY 50 | +0.46 | +0.09 | Trailing 1Y historical sensitivity: a 1% move in NIFTY 50 coincided with a +0.46% co-movement (correlation: 0.09). Descriptive historical relationship, not predictive. |
| USD / INR | -0.25 | -0.03 | Trailing 1Y historical sensitivity: a 1% move in USD / INR coincided with a -0.25% co-movement (correlation: -0.03). Descriptive historical relationship, not predictive. |
| Brent Crude Oil | -0.12 | -0.10 | Trailing 1Y historical sensitivity: a 1% move in Brent Crude Oil coincided with a -0.12% co-movement (correlation: -0.10). Descriptive historical relationship, not predictive. |
| US 10Y Treasury Yield | -0.80 | -0.16 | Trailing 1Y historical sensitivity: a 1% move in US 10Y Treasury Yield coincided with a -0.80% co-movement (correlation: -0.16). Descriptive historical relationship, not predictive. |
How to read Beta & Correlation ( Beta > 1 = wider swings than market; < 1 = calmer )▾
Sensitivities measure historical 1-year regression beta and correlation across paired daily trading sessions over the past 252 trading days. Past relationships can shift over time and do not guarantee future co-movement.
Trailing Returns Breakdown
Calendar-aligned historical percentage performance across standard market windows.
| Period | Start Price | Current Price | Return (%) |
|---|---|---|---|
| 1 Week | ₹168.50 | ₹169.95 | +0.86% |
| 15 Days | ₹156.50 | ₹169.95 | +8.59% |
| 1 Month | ₹154.95 | ₹169.95 | +9.68% |
| 3 Months | ₹178.60 | ₹169.95 | -4.84% |
| 6 Months | ₹205.40 | ₹169.95 | -17.26% |
| 1 Year | ₹125.90 | ₹169.95 | +34.99% |
| 3 Years | ₹125.90 | ₹169.95 | +34.99% |
| 5 Years | ₹125.90 | ₹169.95 | +34.99% |
Price Swings & Biggest Historical Drops
How much this stock typically fluctuates and its largest peak-to-bottom drops over 1 and 5 years.
Calendar-Year Historical Performance
Annual performance breakdown comparing first and last closing sessions of each calendar year.
| Calendar Year | Start Close | End Close | Annual Return | Trajectory Bar |
|---|---|---|---|---|
| CY 2026 | ₹125.90 | ₹169.95 | +35.0% |
Historical Investment Simulator
Factual simulation of past returns in SPECIALITY MEDICINES (SPML) using real recorded closing prices.
Corporate Actions History
No dividend or stock split distributions recorded in historical feeds for SPML.
Recent News & Official Exchange Announcements
Official exchange filings, order wins, and company updates. Click any announcement to see how it affects the business on the right.
Speciality Medicines secures regulatory approval for two new products in Ethiopia - scanx.trade
Speciality Medicines secures regulatory approval for two new products in Ethiopia scanx.trade
Speciality Medicines closes trading window ahead of Q2FY27 results - scanx.trade
Speciality Medicines closes trading window ahead of Q2FY27 results scanx.trade
Speciality Medicines passes all resolutions at fifth annual general meeting - scanx.trade
Speciality Medicines passes all resolutions at fifth annual general meeting scanx.trade
Aurobindo joins speciality pharma race as Indian drugmakers return to branded US play - Moneycontrol.com
Aurobindo joins speciality pharma race as Indian drugmakers return to branded US play Moneycontrol.com
Coal India Ltd soars 0.99%, up for fifth straight session - Business Standard
Coal India Ltd soars 0.99%, up for fifth straight session Business Standard
Why This Matters for the Business
Plain-English breakdown of how the selected announcement connects to revenue, costs, and business drivers.
Verified commercial order win accretive to order-to-bill ratio, securing multi-quarter top-line visibility.
- •Commercial agreement or tender award verified via exchange filing
Volume throughput absorbs fixed manufacturing plant overheads, supporting operating EBITDA margins and cash generation across diversified indian equities units.
Continuous commercial tenders and capital expenditures lock in forward order book-to-bill expansion.
At-a-Glance Health & Momentum Check
While recent announcements reflect past operations, profit margins and return on capital have been tightening as the business absorbs higher costs or new expansion spending.
Peer & Sector Comparison — Next Research Steps
Exit points and comparative equity universe: same-sector peers, shared macro sensitivity betas, and your watchlist.
Common Questions About SPECIALITY MEDICINES (SPML)
Key facts on SPML share price, historical returns, valuation ratios, and past SIP performance.
What is the current share price and 52-week range of SPECIALITY MEDICINES (SPML)?
As of 16 Oct 2026, the official closing share price of SPECIALITY MEDICINES (SPML) on BSE is ₹169.95 (+0.00% vs the previous close). Over the past 52 weeks, SPML has traded between a low of ₹125.90 and a high of ₹363.05, with a reported market capitalization of ₹148.04 Cr.
What are the historical returns of SPECIALITY MEDICINES (SPML)?
Based on split-adjusted closing prices through 16 Oct 2026, SPECIALITY MEDICINES (SPML) recorded the following trailing price returns: 1 Week: +0.86% (from ₹168.50 to ₹169.95); 15 Days: +8.59% (from ₹156.50 to ₹169.95); 1 Month: +9.68% (from ₹154.95 to ₹169.95); 3 Months: -4.84% (from ₹178.60 to ₹169.95); 6 Months: -17.26% (from ₹205.40 to ₹169.95); 1 Year: +34.99% (from ₹125.90 to ₹169.95); 3 Years: +34.99% (from ₹125.90 to ₹169.95); 5 Years: +34.99% (from ₹125.90 to ₹169.95). Past performance reflects historical exchange records and does not predict future returns.
What is the P/E ratio, P/B ratio, and dividend yield of SPECIALITY MEDICINES (SPML)?
SPECIALITY MEDICINES (SPML) currently trades at a trailing Price-to-Earnings (P/E) ratio of 11.3x, a Price-to-Book (P/B) ratio of 2.1x, and a trailing 12-month dividend yield of 0.00%. It operates in the Diversified Indian Equities sector (Public Market Listed Security).
How much would a past lump-sum or monthly SIP investment in SPML have grown?
Based on historical closing prices for SPECIALITY MEDICINES (SPML): A one-time lump-sum investment of ₹1,00,000.00 held for 5 years would be worth ₹1,34,988.08 (+35.0% total return, 73.0% CAGR), while a monthly SIP of ₹10,000.00 over 5 years (total invested: ₹80,000.00) would be worth ₹80,695.22 (+0.9% absolute return). You can test custom amounts and holding periods in the interactive calculator above.
Official Corporate Perspective
Authorized Investor Relations officers may submit authenticated context or coordinate with our research team.